Market Cap | 21.19M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -10.71M | Forward P/E | -2.62 | EPS next Y | 37.00% | 50D Avg Chg | -17.00% |
Sales | 11.9M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | 0.63 | EPS next 5Y | - | 52W High Chg | -71.00% |
Recommedations | 2.00 | Quick Ratio | 6.62 | Shares Outstanding | 12.69M | 52W Low Chg | 7.00% |
Insider Own | 2.95% | ROA | -18.52% | Shares Float | 11.44M | Beta | 1.92 |
Inst Own | 18.53% | ROE | -28.78% | Shares Shorted/Prior | 77.36K/69.66K | Price | 1.65 |
Gross Margin | 56.48% | Profit Margin | -90.01% | Avg. Volume | 589,095 | Target Price | - |
Oper. Margin | -125.40% | Earnings Date | Jul 27 | Volume | 98,425 | Change | -4.62% |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
HC Wainwright & Co. | Buy | Oct 30, 20 |
Aegis Capital | Buy | Nov 25, 20 |
HC Wainwright & Co. | Buy | Nov 25, 20 |
HC Wainwright & Co. | Buy | Nov 25, 20 |
Aegis Capital | Buy | Nov 25, 20 |
Aegis Capital | Buy | Nov 25, 20 |
Cantor Fitzgerald | Overweight | Nov 25, 20 |
H.C. Wainwright | Buy | Nov 25, 20 |
Cantor Fitzgerald | Overweight | Nov 25, 20 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Jun 21 | Option | 0 | 15,599 | 664,361 | 06/22/22 | |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Jun 21 | Sell | 1.74 | 5,330 | 9,274 | 659,031 | 06/22/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Jun 10 | Sell | 1.9 | 6,911 | 13,131 | 648,762 | 06/17/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | May 24 | Sell | 1.7591 | 6,597 | 11,605 | 637,408 | 05/26/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Apr 28 | Sell | 2.4076 | 6,862 | 16,521 | 628,406 | 05/02/22 |
Davis Scott G. | President & COO President & COO | Apr 20 | Sell | 2.6176 | 4,043 | 10,583 | 73,815 | 04/26/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Apr 21 | Option | 0.00 | 15,599 | 635,268 | 04/25/22 | |
GLENN JOHN | Chief Financial Offi.. Chief Financial Officer | Mar 22 | Sell | 2.8197 | 3,462 | 9,762 | 35,130 | 03/28/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Mar 24 | Sell | 2.94 | 6,389 | 18,784 | 619,669 | 03/25/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Mar 21 | Option | 0.00 | 15,599 | 626,058 | 03/22/22 | |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Mar 15 | Sell | 2.5999 | 5,965 | 15,508 | 610,459 | 03/17/22 |
SHERMAN STEVEN | CEO & Chairman CEO & Chairman | Mar 08 | Option | 0.00 | 15,599 | 616,424 | 03/10/22 |